Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.64 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31364552 | 1.00 | KDM4E (0.64) | KDM4ECSNK2A1CA1CA2PTGS2 | |
| SCHEMBL312949 | 0.87 | MAOA (0.53) | KDM4ECA12CA9ALDH1A1CYP3A4 | |
| SCHEMBL29182111 | 0.86 | CSNK2A1 (0.50) | KDM4ECSNK2A1CA1CA2PTGS2 | |
| SCHEMBL7121659 | 0.85 | KDM4E (0.69) | KDM4ECA1CA2CA12CA7 | |
| SCHEMBL4360840 | 0.85 | KDM4E (0.73) | KDM4EPTGS2ALDH1A1CYP3A4PKM | |
| SCHEMBL7262143 | 0.83 | KDM4E (0.66) | KDM4EPTGS2ALDH1A1CYP3A4PKM | |
| SCHEMBL6277588 | 0.83 | ELANE (0.50) | KDM4ECSNK2A1CA1CA2PTGS2 | |
| SCHEMBL8502531 | 0.82 | CA12 (0.61) | KDM4ECA1CA2PTGS2CA12 | |
| SCHEMBL11703537 | 0.81 | CA1 (0.53) | KDM4ECSNK2A1CA1CA2PTGS2 | |
| SCHEMBL1316975 | 0.81 | ALDH1A1 (0.73) | KDM4ECSNK2A1CA1CA2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114573453-B | Selective of Carboxylic ester cleavage process | 荆楚理工学院 | 2024-12-03 | — | — | CN | claimed |
| US-20190192473-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | AmDerma Pharmaceuticals, LLC | 2019-06-27 | — | — | US | claimed |
| US-10278941-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of glioma | AmDerma Pharmaceuticals, LLC (US) | 2019-05-07 | — | — | US | claimed |
| US-20180028484-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | AmDerma Pharmaceuticals, LLC | 2018-02-01 | — | — | US | claimed |
| US-9592216-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of rosacea | AmDerma Pharmaceuticals, LLC (US) | 2017-03-14 | — | — | US | claimed |
| US-20150141476-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | AmDerma Pharmaceuticals, LLC | 2015-05-21 | — | — | US | claimed |
| US-8980869-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of rosacea | AmDerma Pharmaceuticals, LLC (US) | 2015-03-17 | — | — | US | claimed |
| US-20140206654-A1 | USE OF 2,5-DIHYDROXYBENZENE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT OF HEMATOLOGICAL DYSCRASIAS AND CANCER OF AN ORGAN | ACTION MEDICINES, S.L. (ES) | 2014-07-24 | — | — | US | claimed |
| US-20140018330-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | AmDerma Pharmaceuticals, LLC | 2014-01-16 | — | — | US | claimed |
| EP-2061453-B1 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR TREATING CANCERS AND HEMATOLOGICAL DYSCRASIAS | ACTION MEDICINES SL (ES) | 2013-03-13 | — | — | EP | claimed |
| US-20080113947-A1 | 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid, or sultosilic acid for example; combination therapy | ACTION MEDICINES (ES) | 2008-05-15 | — | — | US | claimed |
| US-20080114063-A1 | Use of 2,5-Dihydroxybenzene Derivatives for the Treatment of Tissue Reactive Diseases | ACTION MEDICINES (ES) | 2008-05-15 | — | — | US | claimed |
| WO-2008020039-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR TREATING CANCERS AND HEMATOLOGICAL DYSCRASIAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020031-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ANGIOGENIC DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020037-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING OBESITY, HIRSUTISM, HYPERTRICOSIS AND VIRAL WARTS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020034-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF HEMANGIOMAS OR HEMANGIOBLASTOMAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020040-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF FIBROSIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020042-A1 | USE OF 2, 5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF TISSUE REACTIVE DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020025-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020032-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF OCULAR DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192473-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | CYP8B1, CYP1B1, CYP26B1 | KDM4E 2246/4885CSNK2A1 3367/4885CA1 2993/4885 |
| US-20150141476-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | CYP8B1, CYP1B1, CYP26B1 | KDM4E 2246/4885CSNK2A1 3367/4885CA1 2993/4885 |
| US-20080113947-A1 | 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid, or sultosilic acid for example; combination therapy | ARSA, STS, SULT2A1 | KDM4E 3830/4885CSNK2A1 2448/4885CA1 542/4885 |
| US-20140018330-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | CYP8B1, CYP1B1, CYP26B1 | KDM4E 2246/4885CSNK2A1 3367/4885CA1 2993/4885 |
| US-20080114063-A1 | Use of 2,5-Dihydroxybenzene Derivatives for the Treatment of Tissue Reactive Diseases | CYP11B1, CYP11B2, MYLK | KDM4E 3075/4885CSNK2A1 3185/4885CA1 2355/4885 |
| US-20180028484-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | CYP8B1, CYP1B1, CYP26B1 | KDM4E 2246/4885CSNK2A1 3367/4885CA1 2993/4885 |
| US-20140206654-A1 | USE OF 2,5-DIHYDROXYBENZENE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT OF HEMATOLOGICAL DYSCRASIAS AND CANCER OF AN ORGAN | HMBS, HCLS1, CYP2S1 | KDM4E 821/4885CSNK2A1 2726/4885CA1 2565/4885 |
| US-10278941-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of glioma | ALDH1A2, IDH3A, IDH3B | KDM4E 1649/4885CSNK2A1 3424/4885CA1 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.